NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients

Yohei Iimura, Hitoshi Shimomura, Takeo Yasu, K Imanaka, Ryuichi Ogawa, Akihiko Ito, Kenichi Suzuki, Gaku Yamaguchi, Norihisa Kawasaki, Chimori Konaka

International Journal of Clinical Pharmacology and Therapeutics · 2018 · 10 citations · 0 references

Concepts

Abstract

OBJECTIVES: Skin rash is a common adverse event induced by epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI). Here, we aimed to predict factors that reduce EGFR-TKI-related skin rash. MATERIALS AND METHODS: We conducted a single-center, retrospective study to predict factors that reduce skin rash in patients undergoing treatment for non-small cell lung cancer (NSCLC) with EGFR-TKIs using Cox proportional hazards model. RESULTS: Cox proportional hazard analysis revealed that coadministration of non-steroidal anti-inflammatory drug (NSAID) had protective effects against rash. Steroid coadministration showed a trend to being effective in reducing rash. CONCLUSION: NSAIDs may be useful in preventing EGFR-TKI-related skin rash. .